Evidence map›Paper›PMID 38350010›Full record

ReviewACS nano2024

Environmental and Health Impacts of Graphene and Other Two-Dimensional Materials: A Graphene Flagship Perspective.

Hazel Lin, Tina Buerki-Thurnherr, Jasreen Kaur, Peter Wick, Marco Pelin, Aurelia Tubaro, Fabio Candotto Carniel, Mauro Tretiach, Emmanuel Flahaut, Daniel Iglesias and 22 more

Abstract readReview
In one paragraph

Review in ACS nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Nanoscale advances · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Safety Assessment of Graphene-Based Materials.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Hazel LinCNRS, UPR3572, Immunology, Immunopathology and Therapeutic Chemistry, ISIS, University of Strasbourg, 67000 Strasbourg, France.
Tina Buerki-ThurnherrEmpa, Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Particles-Biology Interactions, 9014 St. Gallen, Switzerland.ORCID 0000-0003-3723-6562
Jasreen KaurNanosafety & Nanomedicine Laboratory, Institute of Environmental Medicine, Karolinska Institutet, 177 77 Stockholm, Sweden.
Peter WickEmpa, Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Particles-Biology Interactions, 9014 St. Gallen, Switzerland.ORCID 0000-0002-0079-4344
Marco PelinDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.ORCID 0000-0002-4306-7411
Aurelia TubaroDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Fabio Candotto CarnielDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.ORCID 0000-0002-8277-4725
Mauro TretiachDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Emmanuel FlahautCIRIMAT, Université de Toulouse, CNRS, INPT, UPS, 31062 Toulouse CEDEX 9, France.ORCID 0000-0001-8344-6902
Daniel IglesiasFacultad de Ciencias y Tecnologías Químicas, Universidad de Castilla-La Mancha (UCLM), 13071 Ciudad Real, Spain.
Ester VázquezFacultad de Ciencias y Tecnologías Químicas, Universidad de Castilla-La Mancha (UCLM), 13071 Ciudad Real, Spain.ORCID 0000-0003-3223-8024
Giada CellotInternational School for Advanced Studies (SISSA), 34136 Trieste, Italy.ORCID 0000-0001-9198-8402
Laura BalleriniInternational School for Advanced Studies (SISSA), 34136 Trieste, Italy.ORCID 0000-0001-8420-0787
Valentina CastagnolaCenter for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, 16132 Genova, Italy.
Fabio BenfenatiCenter for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, 16132 Genova, Italy.ORCID 0000-0002-0653-8368
Andrea ArmirottiAnalytical Chemistry Facility, Istituto Italiano di Tecnologia, 16163 Genoa, Italy.ORCID 0000-0002-3766-8755
Antoine SallustrauDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, SIMoS, Gif-sur-Yvette 91191, France.
Frédéric TaranDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, SIMoS, Gif-sur-Yvette 91191, France.ORCID 0000-0001-5461-329X
Mathilde KeckDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, SIMoS, Gif-sur-Yvette 91191, France.ORCID 0000-0003-4717-3446
Cyrill BussyNanomedicine Lab, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, National Graphene Institute, Manchester M13 9PT, United Kingdom.ORCID 0000-0001-8870-443X
Sandra VranicNanomedicine Lab, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, National Graphene Institute, Manchester M13 9PT, United Kingdom.ORCID 0000-0002-6653-7156
Kostas KostarelosNanomedicine Lab, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, National Graphene Institute, Manchester M13 9PT, United Kingdom.ORCID 0000-0002-2224-6672
Mona ConnollyInstituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), CSIC, Carretera de la Coruña Km 7,5, E-28040 Madrid, Spain.
José Maria NavasInstituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), CSIC, Carretera de la Coruña Km 7,5, E-28040 Madrid, Spain.
Florence MouchetLaboratoire Ecologie Fonctionnelle et Environnement, Université de Toulouse, CNRS, INPT, UPS, 31000 Toulouse, France.
Laury GauthierLaboratoire Ecologie Fonctionnelle et Environnement, Université de Toulouse, CNRS, INPT, UPS, 31000 Toulouse, France.
James BakerTEMAS Solutions GmbH, 5212 Hausen, Switzerland.
Blanca Suarez-MerinoTEMAS Solutions GmbH, 5212 Hausen, Switzerland.
Tomi KanervaFinnish Institute of Occupational Health, 00250 Helsinki, Finland.
Maurizio PratoCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastián, Spain.ORCID 0000-0002-8869-8612
Bengt FadeelNanosafety & Nanomedicine Laboratory, Institute of Environmental Medicine, Karolinska Institutet, 177 77 Stockholm, Sweden.ORCID 0000-0001-5559-8482
Alberto BiancoCNRS, UPR3572, Immunology, Immunopathology and Therapeutic Chemistry, ISIS, University of Strasbourg, 67000 Strasbourg, France.ORCID 0000-0002-1090-296X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two-dimensional (2D) materials have attracted tremendous interest ever since the isolation of atomically thin sheets of graphene in 2004 due to the specific and versatile properties of these materials. However, the increasing production and use of 2D materials necessitate a thorough evaluation of the potential impact on human health and the environment. Furthermore, harmonized test protocols are needed with which to assess the safety of 2D materials. The Graphene Flagship project (2013-2023), funded by the European Commission, addressed the identification of the possible hazard of graphene-based materials as well as emerging 2D materials including transition metal dichalcogenides, hexagonal boron nitride, and others. Additionally, so-called green chemistry approaches were explored to achieve the goal of a safe and sustainable production and use of this fascinating family of nanomaterials. The present review provides a compact survey of the findings and the lessons learned in the Graphene Flagship.

Indexed as

2D nanomaterialsbiodegradabilitycarbon materialsenvironmentexposurehazardsafe-by-designtest guidelinestoxicity

Identifiers

PMID38350010
PMCPMC10906101

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.